186 related articles for article (PubMed ID: 23749641)
1. Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer.
Nobis M; McGhee EJ; Morton JP; Schwarz JP; Karim SA; Quinn J; Edward M; Campbell AD; McGarry LC; Evans TR; Brunton VG; Frame MC; Carragher NO; Wang Y; Sansom OJ; Timpson P; Anderson KI
Cancer Res; 2013 Aug; 73(15):4674-86. PubMed ID: 23749641
[TBL] [Abstract][Full Text] [Related]
2. Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging.
Nobis M; McGhee EJ; Herrmann D; Magenau A; Morton JP; Anderson KI; Timpson P
Cell Adh Migr; 2014; 8(5):478-86. PubMed ID: 25482620
[TBL] [Abstract][Full Text] [Related]
3. Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.
Timpson P; McGhee EJ; Morton JP; von Kriegsheim A; Schwarz JP; Karim SA; Doyle B; Quinn JA; Carragher NO; Edward M; Olson MF; Frame MC; Brunton VG; Sansom OJ; Anderson KI
Cancer Res; 2011 Feb; 71(3):747-57. PubMed ID: 21266354
[TBL] [Abstract][Full Text] [Related]
4. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT
J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
[TBL] [Abstract][Full Text] [Related]
6. A RhoA-FRET Biosensor Mouse for Intravital Imaging in Normal Tissue Homeostasis and Disease Contexts.
Nobis M; Herrmann D; Warren SC; Kadir S; Leung W; Killen M; Magenau A; Stevenson D; Lucas MC; Reischmann N; Vennin C; Conway JRW; Boulghourjian A; Zaratzian A; Law AM; Gallego-Ortega D; Ormandy CJ; Walters SN; Grey ST; Bailey J; Chtanova T; Quinn JMW; Baldock PA; Croucher PI; Schwarz JP; Mrowinska A; Zhang L; Herzog H; Masedunskas A; Hardeman EC; Gunning PW; Del Monte-Nieto G; Harvey RP; Samuel MS; Pajic M; McGhee EJ; Johnsson AE; Sansom OJ; Welch HCE; Morton JP; Strathdee D; Anderson KI; Timpson P
Cell Rep; 2017 Oct; 21(1):274-288. PubMed ID: 28978480
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.
Morton JP; Karim SA; Graham K; Timpson P; Jamieson N; Athineos D; Doyle B; McKay C; Heung MY; Oien KA; Frame MC; Evans TR; Sansom OJ; Brunton VG
Gastroenterology; 2010 Jul; 139(1):292-303. PubMed ID: 20303350
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
[TBL] [Abstract][Full Text] [Related]
11. Significance of ER-Src axis in hormonal therapy resistance.
Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
Araujo J; Logothetis C
Cancer Treat Rev; 2010 Oct; 36(6):492-500. PubMed ID: 20226597
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
16. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
[TBL] [Abstract][Full Text] [Related]
17. Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imaging.
Floerchinger A; Murphy KJ; Latham SL; Warren SC; McCulloch AT; Lee YK; Stoehr J; Mélénec P; Guaman CS; Metcalf XL; Lee V; Zaratzian A; Da Silva A; Tayao M; Rolo S; Phimmachanh M; Sultani G; McDonald L; Mason SM; Ferrari N; Ooms LM; Johnsson AE; Spence HJ; Olson MF; Machesky LM; Sansom OJ; Morton JP; Mitchell CA; Samuel MS; Croucher DR; Welch HCE; Blyth K; Caldon CE; Herrmann D; Anderson KI; Timpson P; Nobis M
Cell Rep; 2021 Sep; 36(11):109689. PubMed ID: 34525350
[TBL] [Abstract][Full Text] [Related]
18. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Rice L; Lepler S; Pampo C; Siemann DW
Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G
Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945
[TBL] [Abstract][Full Text] [Related]
20. Removing physiological motion from intravital and clinical functional imaging data.
Warren SC; Nobis M; Magenau A; Mohammed YH; Herrmann D; Moran I; Vennin C; Conway JR; Mélénec P; Cox TR; Wang Y; Morton JP; Welch HC; Strathdee D; Anderson KI; Phan TG; Roberts MS; Timpson P
Elife; 2018 Jul; 7():. PubMed ID: 29985127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
